121 related articles for article (PubMed ID: 126576)
1. Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.
Vogt W; Schmidt G; Dieminger L; Lynen R
Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(5):440-55. PubMed ID: 126576
[TBL] [Abstract][Full Text] [Related]
2. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
3. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. II. Physico-chemical characterization of the activated complex.
Miyama A; Kato T; Yokoo J; Kashiba S
Biken J; 1975 Dec; 18(4):205-14. PubMed ID: 1218075
[TBL] [Abstract][Full Text] [Related]
4. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
[TBL] [Abstract][Full Text] [Related]
5. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
6. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
7. Interaction of C3b, B, and D in the alternative pathway of complement activation.
Nicholson A; Brade V; Schorlemmer HU; Burger R; Bitter-Suermann D; Hadding U
J Immunol; 1975 Oct; 115(4):1108-13. PubMed ID: 240884
[TBL] [Abstract][Full Text] [Related]
8. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
Ruddy S; Austen KF; Goetzl EJ
J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
10. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1982 Dec; 129(6):2603-7. PubMed ID: 6923908
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
[TBL] [Abstract][Full Text] [Related]
12. Action of the C3b-inactivator on the cell-bound C3b.
Law SK; Fearon DT; Levine RP
J Immunol; 1979 Mar; 122(3):759-65. PubMed ID: 448074
[TBL] [Abstract][Full Text] [Related]
13. Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly.
Nicholson A; Brade V; Lee GD; Shin HS; Mayer MM
J Immunol; 1974 Mar; 112(3):1115-23. PubMed ID: 4811964
[No Abstract] [Full Text] [Related]
14. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
16. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway.
Hung SL; Peng C; Kostavasili I; Friedman HM; Lambris JD; Eisenberg RJ; Cohen GH
Virology; 1994 Sep; 203(2):299-312. PubMed ID: 8053154
[TBL] [Abstract][Full Text] [Related]
17. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
[TBL] [Abstract][Full Text] [Related]
18. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
Medicus RG; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
Adam C; Williams DG; Peters DK
Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
[TBL] [Abstract][Full Text] [Related]
20. Properdin: initiation of alternative complement pathway.
Fearon DT; Austen KF
Proc Natl Acad Sci U S A; 1975 Aug; 72(8):3220-4. PubMed ID: 1059108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
